Status:
COMPLETED
Use of Botulinum Toxin to Treat Psoriasis
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
Allergan
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoria...
Eligibility Criteria
Inclusion
- Healthy subjects. Psoriasis vulgaris diagnosis made by a board certified dermatologist involving at least one area that has been intolerant or recalcitrant to at least two forms of recognized topical or systemic treatments in the past. In addition, the subject should have at least a score of 2 for keratoderma and erythema. Signed informed consent. Willing to adhere to protocol.
Exclusion
- Immunosuppressed patients, pregnant, secondary skin infections, phototherapy within 4 weeks of the botulinum toxin injection, exposure to any topical or systemic retinoid treatment with the last 12 months, volunteers taking chloroquine and hydroxychloroquine, volunteers on warfarin.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00816517
Start Date
January 1 2009
End Date
December 1 2015
Last Update
April 4 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Univerisity of Minnesota
Minneapolis, Minnesota, United States, 55444